Organization · Private Equity
Belnord Capital
Belnord Capital is an independent alternatives investment firm based in Stockholm, Sweden, established in 2023. The firm specializes in private equity, focusing on GP solutions, secondaries, and co-investments.
Overview
What Belnord Capital does
What Belnord Capital is
Belnord Capital is an independent alternatives investment firm based in Stockholm, Sweden, established in 2023. The firm specializes in private equity, focusing on GP solutions, secondaries, and co-investments.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Private Equity
- Founded
- Founded in 2023
- Approximate age
- About 3 years
- Structured capabilities
- Funder
- Last reviewed
- March 3, 2026
Official channels
Find Belnord Capital elsewhere
Open the official website or a supported primary organization account.
Capability profile
Belnord Capital as a funder
Investment thesis
Belnord Capital invests in sponsor-led transactions, continuation vehicles, direct investments, co-investments, and other liquidity solutions. The firm employs a hands-on investment approach and leverages a strong network to access high-quality deal flow.
Focus narrative
Belnord Capital invests in sponsor-led transactions, continuation vehicles, direct investments, co-investments, and other liquidity solutions. The firm employs a hands-on investment approach and leverages a strong network to access high-quality deal flow.
Focus and fit
- Regions
- Europe
Availability
- Currently deploying
- Not published
Portfolio and track record
- Recorded portfolio count
- 4
Portfolio context
Medix Biochemica: A global leader in critical components for diagnostic tests, headquartered in Finland. Founded in 1985, the company develops and supplies high-quality antibodies, antigens, and other raw materials for the in vitro diagnostics industry. Immedica: A pharmaceutical company based in Sweden, founded in 2018, specializing in the commercialization of medicines for rare diseases and specialty care. Immedica distributes a portfolio of approximately 25 drugs across Europe and the Middle East, focusing on genetic and metabolic diseases, oncology, and ophthalmology. Yaveon: An independent software vendor and system integrator based in Germany, founded in 2008. Yaveon specializes in the Microsoft Dynamics ERP platform and serves small and medium companies in the process manufacturing industry, particularly in life sciences. Syclef: A French company founded in 2003, specializing in the installation and maintenance of refrigeration and air conditioning systems. Syclef focuses on medium and large refrigeration installations and plays a key role in the energy transition by utilizing sustainable technologies.
Common questions
What to know about Belnord Capital
Upseed classifies Belnord Capital under the Private Equity organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
March 3, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.